EP-1873

EP-1873 is a **synthetic peptide** drug candidate developed originally by EPIX Pharmaceuticals. It functions as a **fibrinogen modulator**, targeting fibrinogen in order to modulate processes involved in blood clot formation. The agent has been investigated for cardiovascular applications, particularly in the context of venous thrombosis and related thrombotic disorders, and has been studied in the context of molecular imaging of thrombosis. There is no evidence of regulatory approval or clinical phase advancement beyond pending, and the latest public profile lists its development status as pending. The main indication identified is cardiovascular disease, with historical research focus on venous thrombosis[1].